aducanumab – Patient Worthy

stevepb / Pixabay

EMA Accepts MAA For Aducanumab, an Alzheimer’s Disease Treatment

Post author:Kendall Mason
Post published:November 12, 2020
Post category:Alzheimer's disease without Neurofibrillary tangles

The European Medicines Agency has accepted Biogen's Marketing Authorization Application (MAA) for review. The application is for aducanumab, a treatment for Alzheimer's disease. As this condition faces an unmet medical…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More